Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasms, Plasma Cell × daratumumab × Clear all

Phase

Status

Active not recruiting 5 Completed 3 Unknown 2 Withdrawn 1 Terminated 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 5 Prostatic Neoplasms 1 Neoplasms, Plasma Cell 1 Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic 1 Leukemia, Plasma Cell 1 Hematologic Neoplasms 1

Interventions

Melphalan 5 Dexamethasone 4 Bortezomib 3 Arsenic Trioxide 3 fludarabine phosphate 2 Vorinostat 2 Stem Cell Transplantation 2 Peripheral Blood Stem Cell Transplantation 2 Lenalidomide 2 Drug Therapy 2 Busulfan 2 Ascorbic Acid 2 ogalvibart 1 ethanolamine oleate 1 daratumumab 1 crexavibart 1 carfilzomib 1 Zoledronic Acid 1 Trimethoprim, Sulfamethoxazole Drug Combination 1 Trimethoprim 1 Therapeutics 1 Thalidomide 1 Tacrolimus 1 Surveys and Questionnaires 1 Sulfamethoxazole 1 Sodium Chloride 1 Simvastatin 1 Saline Solution, Hypertonic 1 Saline Solution 1 Rituximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04024384 2020-03-27

DARALLO

Assistance Publique - Hôpitaux de Paris

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡